Updates are available Correction dated 2024-10-16
Click to view Correction: https://doi.org/10.1038/s41586-024-08200-7
-
Authors
Chen, Xiaoying http://orcid.org/0000-0002-6710-3798
Firulyova, Maria
Manis, Melissa
Herz, Jasmin http://orcid.org/0000-0001-6325-863X
Smirnov, Igor
Aladyeva, Ekaterina http://orcid.org/0000-0002-3483-6944
Wang, Chanung
Bao, Xin
Finn, Mary Beth
Hu, Hao
Shchukina, Irina
Kim, Min Woo
Yuede, Carla M.
Kipnis, Jonathan http://orcid.org/0000-0002-3714-517X
Artyomov, Maxim N. http://orcid.org/0000-0002-1133-4212
Ulrich, Jason D. http://orcid.org/0000-0002-4743-926X
Holtzman, David M. http://orcid.org/0000-0002-3400-0856
- License Information
-
More Information
Article History
Received: 17 January 2022
Accepted: 3 February 2023
First Online: 8 March 2023
Change Date: 16 October 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41586-024-08200-7
Competing interests
: D.M.H. is an inventor on a patent licensed by Washington University to C2N Diagnostics on the therapeutic use of anti-tau antibodies. D.M.H. co-founded and is on the scientific advisory board of C2N Diagnostics. D.M.H. is on the scientific advisory board of Denali and Cajal Neuroscience and consults for Genentech and Alector. J.K. is a member of a scientific advisory group for PureTech. All other authors declare no competing interests.
